問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

Recruiting Trial

1,316Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

3138Cases

2019-01-01 - 2020-02-05

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-01-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-02-01 - 2016-01-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-01-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2018-01-01 - 2019-12-31

Others

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.

  • Condition/Disease

    Angina

  • Test Drug

    Ranolazine

Participate Sites
3Sites

Terminated3Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2012-05-15 - 2014-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2021-04-01 - 2022-07-31

Phase II/III

A Phase 2/3, multi-center, double-blind, placebo-controlled, randomized, parallel-group, dose-response comparison of the efficacy and safety of a topical rapamycin cream for the treatment of facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC) in patients 6 years of age and over.

  • Condition/Disease

    facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC)

  • Test Drug

    Rapamycin

Participate Sites
1Sites

Recruiting1Sites

2014-03-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-05-01 - 2018-02-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-01-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

1 250 251 252 253 254 314
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB